Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Market Potential | Analyst targets range from $3.91 to $6.89, reflecting optimism about Arbutus's position in the competitive CHB treatment landscape |
Financial Outlook | Delve into Arbutus's strategic moves to extend its financial runway into Q4 2026, balancing cost-cutting measures with ambitious clinical goals |
Clinical Promise | Explore imdusiran's potential as a groundbreaking CHB therapy, with recent trials showing promising results in combination with other treatments |
Hepatitis B Focus | Arbutus Biopharma narrows its focus to chronic hepatitis B treatments, particularly its lead siRNA candidate imdusiran, streamlining operations for efficiency |
Metrics to compare | ABUS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipABUSPeersSector | |
---|---|---|---|---|
P/E Ratio | −8.6x | −3.0x | −0.5x | |
PEG Ratio | −1.19 | −0.10 | 0.00 | |
Price / Book | 8.3x | 1.6x | 2.6x | |
Price / LTM Sales | 103.2x | 3.9x | 3.1x | |
Upside (Analyst Target) | 46.9% | 107.6% | 48.6% | |
Fair Value Upside | Unlock | 22.7% | 8.9% | Unlock |